<!DOCTYPE html>
<html lang="" xml:lang="">
  <head>
    <title>MS Thesis</title>
    <meta charset="utf-8" />
    <meta name="author" content="" />
    <script src="MS-Thesis-Presentation_files/kePrint-0.0.1/kePrint.js"></script>
    <link href="MS-Thesis-Presentation_files/bsTable-3.3.7/bootstrapTable.min.css" rel="stylesheet" />
    <link rel="stylesheet" href="AC_theme.css" type="text/css" />
    <link rel="stylesheet" href="AC_theme_add.css" type="text/css" />
  </head>
  <body>
    <textarea id="source">




class: title-slide, middle
## Use of Trajectory Cluster Analysis to Identify Subgroups of Pediatric Crohn's Disease
&lt;hr color='#70c0b1' size=2em&gt;
### Andrew Chen
### Advised by Jing Huang, PhD
### In collaboration with Ronen Stein, MD

---

## Motivation
- Crohn's disease (CD) is a severe chronic inflammatory bowel disease
    - Affects as many as 780,000 Americans[&lt;sup&gt;1&lt;/sup&gt;](https://www.chop.edu/conditions-diseases/crohns-disease)
    - Recently recognized as one of the most important chronic conditions in children
- Treatment and clinical presentation of Pediatric CD are highly heterogeneous

&lt;br /&gt;
.center[![:scale 60%](Figures/gi-tract-normal-vs-crohns-cropped-16x9.jpg)]
---

## Longitudinal Subtyping of Pediatric CD
.footnote[
&lt;sup&gt;1&lt;/sup&gt;[Weiser et al., 2018](https://dx.doi.org/10.1136%2Fgutjnl-2016-312518)  
&lt;sup&gt;2&lt;/sup&gt;[Mossotto et al., 2017](https://www.nature.com/articles/s41598-017-02606-2)
]
.pull-left[
- Previous research primarily utilized cross-sectional data including gene expression&lt;sup&gt;1&lt;/sup&gt;, endoscopic, and histological samples&lt;sup&gt;2&lt;/sup&gt;
- Researchers have yet to leverage longitudinal electronic health record (EHR) in subtyping
]
--
.pull-right[
- EHRs at Children's Hospital of Philadelphia (CHOP) include
    - **C-reactive protein (CRP)**
    - Calprotectin
    - Infliximab concentration
]
--
&lt;img src="MS-Thesis-Presentation_files/figure-html/raw_crp-1.svg" style="display: block; margin: auto;" /&gt;
---

## Trajectory Cluster Analysis
**Step 1**: Perform functional principal components analysis (FPCA) on CRP values to identify unique patterns of disease trajectory in the study population
--


**Step 2**: Cluster using a Gaussian mixture model to identify subgroups of pediatric CD patients
--

- Shown to have strong performance compared to other functional clustering techniques&lt;sup&gt;1&lt;/sup&gt;
- Chose number of FPCs that explain 75% of the variation
- Follow-up analyses examined distributions of patient characteristics and long-term outcomes
    - Chi-squared tests for categorical variables
    - One-way ANOVA for continuous variables
- Other follow-up analyses consisted of Cox regression of long-term outcomes on known clinical covariates and subtype assignment

.footnote[
&lt;sup&gt;1&lt;/sup&gt;[Jacques and Preda, 2014](https://doi.org/10.1007/s11634-013-0158-y)
]

---

## Study Design and Demographics
.pull-left[
- Obtained EHRs from children with diagnosis of pediatric CD between 2009 and 2017
    - Also started on Remicade (infliximab) therapy between January 2010 and December 2017
- Excluded patients with less than two CRP measurements within 2.5 years of diagnosis
- Defined early onset as having been diagnosed before age five
]
.pull-right[.small[


&lt;table&gt;
 &lt;thead&gt;
  &lt;tr&gt;
   &lt;th style="text-align:left;"&gt; Variables &lt;/th&gt;
   &lt;th style="text-align:left;"&gt; Overall &lt;/th&gt;
  &lt;/tr&gt;
 &lt;/thead&gt;
&lt;tbody&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left;"&gt; Number of Subjects &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 404 &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left;"&gt; Male (%) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 242 (59.9) &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left;"&gt; Age at diagnosis, mean (SD) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 12.62 (3.34) &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left;"&gt; Early Onset (%) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 10 (2.5) &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left;"&gt; Baseline Phenotype (%) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt;  &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left; padding-left: 2em;" indentlevel="1"&gt; Stricturing and Penetrating &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 25 (6.2) &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left; padding-left: 2em;" indentlevel="1"&gt; Inflammatory &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 300 (74.3) &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left; padding-left: 2em;" indentlevel="1"&gt; Penetrating &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 28 (6.9) &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left; padding-left: 2em;" indentlevel="1"&gt; Stricturing &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 51 (12.6) &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left;"&gt; Perianal (%) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 61 (15.1) &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left;"&gt; Type of Combination Therapy (%) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt;  &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left; padding-left: 2em;" indentlevel="1"&gt; Azathioprine &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 15 (3.7) &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left; padding-left: 2em;" indentlevel="1"&gt; Mercaptopurine &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 19 (4.7) &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left; padding-left: 2em;" indentlevel="1"&gt; Methotrexate &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 109 (27.0) &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left; padding-left: 2em;" indentlevel="1"&gt; None &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 261 (64.6) &lt;/td&gt;
  &lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;
]]
---

## FPCA Results


&lt;img src="MS-Thesis-Presentation_files/figure-html/unnamed-chunk-1-1.svg" width="80%" style="display: block; margin: auto;" /&gt;
---

## Subgrouping Results
&lt;img src="MS-Thesis-Presentation_files/figure-html/mean_clust-1.svg" style="display: block; margin: auto;" /&gt;

&lt;img src="MS-Thesis-Presentation_files/figure-html/raw_clust-1.svg" style="display: block; margin: auto;" /&gt;
---

## Subgrouping Results: Comparisons


.small[
&lt;table&gt;
 &lt;thead&gt;
  &lt;tr&gt;
   &lt;th style="text-align:left;"&gt; Variables &lt;/th&gt;
   &lt;th style="text-align:left;"&gt; 1 &lt;/th&gt;
   &lt;th style="text-align:left;"&gt; 2 &lt;/th&gt;
   &lt;th style="text-align:left;"&gt; 3 &lt;/th&gt;
   &lt;th style="text-align:left;"&gt; 4 &lt;/th&gt;
   &lt;th style="text-align:left;"&gt; p &lt;/th&gt;
  &lt;/tr&gt;
 &lt;/thead&gt;
&lt;tbody&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left;"&gt; Number of Subjects &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 36 &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 103 &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 222 &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 43 &lt;/td&gt;
   &lt;td style="text-align:left;"&gt;  &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left;"&gt; Male (%) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 17 (47.2) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 65 (63.1) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 133 (59.9) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 27 (62.8) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 0.392 &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left;"&gt; Age at diagnosis, mean (SD) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 12.88 (3.54) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 12.44 (3.34) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 12.74 (3.38) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 12.21 (3.03) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 0.690 &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left;"&gt; Early Onset (%) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 1 (2.8) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 3 (2.9) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 6 (2.7) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 0 (0.0) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 0.745 &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left;"&gt; Baseline Phenotype (%) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt;  &lt;/td&gt;
   &lt;td style="text-align:left;"&gt;  &lt;/td&gt;
   &lt;td style="text-align:left;"&gt;  &lt;/td&gt;
   &lt;td style="text-align:left;"&gt;  &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; &amp;lt;0.001 &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left; padding-left: 2em;" indentlevel="1"&gt; Stricturing and Penetrating &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 8 (22.2) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 4 (3.9) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 12 (5.4) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 0 (0.0) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt;  &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left; padding-left: 2em;" indentlevel="1"&gt; Inflammatory &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 19 (52.8) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 84 (81.6) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 180 (81.1) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 40 (93.0) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt;  &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left; padding-left: 2em;" indentlevel="1"&gt; Penetrating &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 4 (11.1) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 6 (5.8) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 6 (2.7) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 1 (2.3) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt;  &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left; padding-left: 2em;" indentlevel="1"&gt; Stricturing &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 5 (13.9) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 9 (8.7) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 24 (10.8) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 2 (4.7) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt;  &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left;"&gt; Ileocolonoscopy at 10 years (%) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 12 (33.3) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 14 (13.6) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 15 (6.8) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 2 (4.7) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; &amp;lt;0.001 &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left;"&gt; Surgery at 10 years (%) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 6 (16.7) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 10 (9.7) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 12 (5.4) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 1 (2.3) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 0.038 &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left;"&gt; Type of Combination Therapy (%) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt;  &lt;/td&gt;
   &lt;td style="text-align:left;"&gt;  &lt;/td&gt;
   &lt;td style="text-align:left;"&gt;  &lt;/td&gt;
   &lt;td style="text-align:left;"&gt;  &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 0.205 &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left; padding-left: 2em;" indentlevel="1"&gt; Azathioprine &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 1 (2.8) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 8 (7.8) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 6 (2.7) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 0 (0.0) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt;  &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left; padding-left: 2em;" indentlevel="1"&gt; Mercaptopurine &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 0 (0.0) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 6 (5.8) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 11 (5.0) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 2 (4.7) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt;  &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left; padding-left: 2em;" indentlevel="1"&gt; Methotrexate &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 10 (27.8) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 30 (29.1) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 61 (27.5) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 8 (18.6) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt;  &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left; padding-left: 2em;" indentlevel="1"&gt; None &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 25 (69.4) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 59 (57.3) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 144 (64.9) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 33 (76.7) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt;  &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left;"&gt; Baseline CRP, mean (SD) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 10.00 (10.38) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 4.88 (4.22) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 2.88 (3.05) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 2.53 (2.89) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; &amp;lt;0.001 &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left;"&gt; Remicade Start, mean (SD) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 0.78 (0.88) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 1.06 (1.34) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 0.86 (1.27) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 0.45 (0.85) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 0.057 &lt;/td&gt;
  &lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;
]
---

## Subgrouping Results: Comparisons
.small[
&lt;table&gt;
 &lt;thead&gt;
  &lt;tr&gt;
   &lt;th style="text-align:left;"&gt; Variables &lt;/th&gt;
   &lt;th style="text-align:left;"&gt; 1 &lt;/th&gt;
   &lt;th style="text-align:left;"&gt; 2 &lt;/th&gt;
   &lt;th style="text-align:left;"&gt; 3 &lt;/th&gt;
   &lt;th style="text-align:left;"&gt; 4 &lt;/th&gt;
   &lt;th style="text-align:left;"&gt; p &lt;/th&gt;
  &lt;/tr&gt;
 &lt;/thead&gt;
&lt;tbody&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left;"&gt; Number of Subjects &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 36 &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 103 &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 222 &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 43 &lt;/td&gt;
   &lt;td style="text-align:left;"&gt;  &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left;"&gt; Male (%) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 17 (47.2) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 65 (63.1) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 133 (59.9) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 27 (62.8) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 0.392 &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left;"&gt; Age at diagnosis, mean (SD) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 12.88 (3.54) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 12.44 (3.34) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 12.74 (3.38) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 12.21 (3.03) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 0.690 &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left;"&gt; Early Onset (%) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 1 (2.8) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 3 (2.9) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 6 (2.7) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 0 (0.0) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 0.745 &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left;font-weight: bold;color: #70c0b1 !important;"&gt; Baseline Phenotype (%) &lt;/td&gt;
   &lt;td style="text-align:left;font-weight: bold;color: #70c0b1 !important;"&gt;  &lt;/td&gt;
   &lt;td style="text-align:left;font-weight: bold;color: #70c0b1 !important;"&gt;  &lt;/td&gt;
   &lt;td style="text-align:left;font-weight: bold;color: #70c0b1 !important;"&gt;  &lt;/td&gt;
   &lt;td style="text-align:left;font-weight: bold;color: #70c0b1 !important;"&gt;  &lt;/td&gt;
   &lt;td style="text-align:left;font-weight: bold;color: #70c0b1 !important;"&gt; &amp;lt;0.001 &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left; padding-left: 2em;font-weight: bold;color: #70c0b1 !important;" indentlevel="1"&gt; Stricturing and Penetrating &lt;/td&gt;
   &lt;td style="text-align:left;font-weight: bold;color: #70c0b1 !important;"&gt; 8 (22.2) &lt;/td&gt;
   &lt;td style="text-align:left;font-weight: bold;color: #70c0b1 !important;"&gt; 4 (3.9) &lt;/td&gt;
   &lt;td style="text-align:left;font-weight: bold;color: #70c0b1 !important;"&gt; 12 (5.4) &lt;/td&gt;
   &lt;td style="text-align:left;font-weight: bold;color: #70c0b1 !important;"&gt; 0 (0.0) &lt;/td&gt;
   &lt;td style="text-align:left;font-weight: bold;color: #70c0b1 !important;"&gt;  &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left; padding-left: 2em;font-weight: bold;color: #70c0b1 !important;" indentlevel="1"&gt; Inflammatory &lt;/td&gt;
   &lt;td style="text-align:left;font-weight: bold;color: #70c0b1 !important;"&gt; 19 (52.8) &lt;/td&gt;
   &lt;td style="text-align:left;font-weight: bold;color: #70c0b1 !important;"&gt; 84 (81.6) &lt;/td&gt;
   &lt;td style="text-align:left;font-weight: bold;color: #70c0b1 !important;"&gt; 180 (81.1) &lt;/td&gt;
   &lt;td style="text-align:left;font-weight: bold;color: #70c0b1 !important;"&gt; 40 (93.0) &lt;/td&gt;
   &lt;td style="text-align:left;font-weight: bold;color: #70c0b1 !important;"&gt;  &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left; padding-left: 2em;font-weight: bold;color: #70c0b1 !important;" indentlevel="1"&gt; Penetrating &lt;/td&gt;
   &lt;td style="text-align:left;font-weight: bold;color: #70c0b1 !important;"&gt; 4 (11.1) &lt;/td&gt;
   &lt;td style="text-align:left;font-weight: bold;color: #70c0b1 !important;"&gt; 6 (5.8) &lt;/td&gt;
   &lt;td style="text-align:left;font-weight: bold;color: #70c0b1 !important;"&gt; 6 (2.7) &lt;/td&gt;
   &lt;td style="text-align:left;font-weight: bold;color: #70c0b1 !important;"&gt; 1 (2.3) &lt;/td&gt;
   &lt;td style="text-align:left;font-weight: bold;color: #70c0b1 !important;"&gt;  &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left; padding-left: 2em;font-weight: bold;color: #70c0b1 !important;" indentlevel="1"&gt; Stricturing &lt;/td&gt;
   &lt;td style="text-align:left;font-weight: bold;color: #70c0b1 !important;"&gt; 5 (13.9) &lt;/td&gt;
   &lt;td style="text-align:left;font-weight: bold;color: #70c0b1 !important;"&gt; 9 (8.7) &lt;/td&gt;
   &lt;td style="text-align:left;font-weight: bold;color: #70c0b1 !important;"&gt; 24 (10.8) &lt;/td&gt;
   &lt;td style="text-align:left;font-weight: bold;color: #70c0b1 !important;"&gt; 2 (4.7) &lt;/td&gt;
   &lt;td style="text-align:left;font-weight: bold;color: #70c0b1 !important;"&gt;  &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left;font-weight: bold;color: #70c0b1 !important;"&gt; Ileocolonoscopy at 10 years (%) &lt;/td&gt;
   &lt;td style="text-align:left;font-weight: bold;color: #70c0b1 !important;"&gt; 12 (33.3) &lt;/td&gt;
   &lt;td style="text-align:left;font-weight: bold;color: #70c0b1 !important;"&gt; 14 (13.6) &lt;/td&gt;
   &lt;td style="text-align:left;font-weight: bold;color: #70c0b1 !important;"&gt; 15 (6.8) &lt;/td&gt;
   &lt;td style="text-align:left;font-weight: bold;color: #70c0b1 !important;"&gt; 2 (4.7) &lt;/td&gt;
   &lt;td style="text-align:left;font-weight: bold;color: #70c0b1 !important;"&gt; &amp;lt;0.001 &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left;font-weight: bold;color: #70c0b1 !important;"&gt; Surgery at 10 years (%) &lt;/td&gt;
   &lt;td style="text-align:left;font-weight: bold;color: #70c0b1 !important;"&gt; 6 (16.7) &lt;/td&gt;
   &lt;td style="text-align:left;font-weight: bold;color: #70c0b1 !important;"&gt; 10 (9.7) &lt;/td&gt;
   &lt;td style="text-align:left;font-weight: bold;color: #70c0b1 !important;"&gt; 12 (5.4) &lt;/td&gt;
   &lt;td style="text-align:left;font-weight: bold;color: #70c0b1 !important;"&gt; 1 (2.3) &lt;/td&gt;
   &lt;td style="text-align:left;font-weight: bold;color: #70c0b1 !important;"&gt; 0.038 &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left;"&gt; Type of Combination Therapy (%) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt;  &lt;/td&gt;
   &lt;td style="text-align:left;"&gt;  &lt;/td&gt;
   &lt;td style="text-align:left;"&gt;  &lt;/td&gt;
   &lt;td style="text-align:left;"&gt;  &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 0.205 &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left; padding-left: 2em;" indentlevel="1"&gt; Azathioprine &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 1 (2.8) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 8 (7.8) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 6 (2.7) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 0 (0.0) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt;  &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left; padding-left: 2em;" indentlevel="1"&gt; Mercaptopurine &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 0 (0.0) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 6 (5.8) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 11 (5.0) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 2 (4.7) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt;  &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left; padding-left: 2em;" indentlevel="1"&gt; Methotrexate &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 10 (27.8) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 30 (29.1) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 61 (27.5) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 8 (18.6) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt;  &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left; padding-left: 2em;" indentlevel="1"&gt; None &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 25 (69.4) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 59 (57.3) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 144 (64.9) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 33 (76.7) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt;  &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left;"&gt; Baseline CRP, mean (SD) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 10.00 (10.38) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 4.88 (4.22) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 2.88 (3.05) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 2.53 (2.89) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; &amp;lt;0.001 &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left;"&gt; Remicade Start, mean (SD) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 0.78 (0.88) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 1.06 (1.34) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 0.86 (1.27) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 0.45 (0.85) &lt;/td&gt;
   &lt;td style="text-align:left;"&gt; 0.057 &lt;/td&gt;
  &lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;
]
---

## Cluster 1: Non-responder Patients
&lt;img src="MS-Thesis-Presentation_files/figure-html/cl1-1.svg" style="display: block; margin: auto;" /&gt;
- Characterized by high baseline CRP (mean 10.38 mg/dL) and frequent relapses after diagnosis
- Higher proportion of non-inflammatory disease phenotypes, with more patients having penetrating, stricturing, or both phenotypes (n = 17, 47.2%)
- Highest proportion of patients of receiving ileocolonoscopy (33.3%) or other surgeries (16.7%)
---

## Cluster 2: Patients with moderate disease control
&lt;img src="MS-Thesis-Presentation_files/figure-html/cl2-1.svg" style="display: block; margin: auto;" /&gt;
- Less severe disease activity at the baseline (mean CRP 4.88 mg/dL) and moderate disease control over the study period
- Higher rate of having an ileocolonoscopy performed (13.6%)

---

## Cluster 3: Patients with well-controlled disease
&lt;img src="MS-Thesis-Presentation_files/figure-html/cl3-1.svg" style="display: block; margin: auto;" /&gt;
- Low baseline CRP (mean 2.88 mg/dL) and good disease control
- Lesser proportion of patients on combined therapy (35.1%) compared to Subgroup 2 (42.7%). 

---

## Cluster 4: Patients with less severe disease
&lt;img src="MS-Thesis-Presentation_files/figure-html/cl4-1.svg" style="display: block; margin: auto;" /&gt;
- Lowest baseline CRP (mean 2.53) as well as the highest proportion of inflammatory (93.0%)
- Proportion undergoing ileocolonoscopy (4.7%) or other surgeries (2.3%) were the lowest out of all the subgroups
- Lowest proportion on combined therapy (23.3%)
---

## Ileocolonoscopy Analysis
.pull-left[
&lt;img src="MS-Thesis-Presentation_files/figure-html/ileo-1.svg" width="100%" /&gt;
]
.pull-right[
![](MS-Thesis-Presentation_files/figure-html/ileo_phenotype-1.svg)&lt;!-- --&gt;
]
---

## Ileocolonoscopy Analysis: Cox Regression
.pull-left[
- Cox regression fit including sex, age at diagnosis, phenotype, and subgroup
- Likelihood ratio test shows that addition of subgroup improves model fit (*p* = 0.0035)
]
.pull-right[
&lt;table&gt;
 &lt;thead&gt;
  &lt;tr&gt;
   &lt;th style="text-align:left;"&gt; Variables &lt;/th&gt;
   &lt;th style="text-align:right;"&gt; Hazard Ratio &lt;/th&gt;
   &lt;th style="text-align:right;"&gt; p &lt;/th&gt;
  &lt;/tr&gt;
 &lt;/thead&gt;
&lt;tbody&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left;"&gt; Male &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 1.087 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 0.788 &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left;"&gt; Age at Diagnosis &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 1.150 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 0.022 &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left;font-weight: bold;color: #70c0b1 !important;"&gt; Inflammatory &lt;/td&gt;
   &lt;td style="text-align:right;font-weight: bold;color: #70c0b1 !important;"&gt; 0.035 &lt;/td&gt;
   &lt;td style="text-align:right;font-weight: bold;color: #70c0b1 !important;"&gt; 0.000 &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left;"&gt; Penetrating &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 0.265 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 0.023 &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left;"&gt; Stricturing &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 1.066 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 0.860 &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left;"&gt; Subgroup 2 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 0.979 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 0.959 &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left;font-weight: bold;color: #70c0b1 !important;"&gt; Subgroup 3 &lt;/td&gt;
   &lt;td style="text-align:right;font-weight: bold;color: #70c0b1 !important;"&gt; 0.409 &lt;/td&gt;
   &lt;td style="text-align:right;font-weight: bold;color: #70c0b1 !important;"&gt; 0.028 &lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
   &lt;td style="text-align:left;"&gt; Subgroup 4 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 0.350 &lt;/td&gt;
   &lt;td style="text-align:right;"&gt; 0.178 &lt;/td&gt;
  &lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;
]
---

## Conclusions
- Pediatric CD can be divided into subgroups using available EHR data
- These subgroups distinguish levels of disease control beyond baseline patient characteristics and treatment information
    - Provide additional insight into long-term outcomes
--


- Further investigation could enable earlier detection of these subgroups
- Potentially could be used to tailor treatment regimens
--


### Acknowledgements
Huge thanks to Jing for suggesting and supervising this project.

Additional thanks to Yong for his advice and Ronen for his help in interpretting results and sharing his extensive clinical knowledge.
    </textarea>
<style data-target="print-only">@media screen {.remark-slide-container{display:block;}.remark-slide-scaler{box-shadow:none;}}</style>
<script src="https://remarkjs.com/downloads/remark-latest.min.js"></script>
<script src="macros.js"></script>
<script>var slideshow = remark.create({
"ratio": "16:9",
"highlightStyle": "tomorrow-night-bright",
"countIncrementalSlides": false,
"slideNumberFormat": "%current%"
});
if (window.HTMLWidgets) slideshow.on('afterShowSlide', function (slide) {
  window.dispatchEvent(new Event('resize'));
});
(function(d) {
  var s = d.createElement("style"), r = d.querySelector(".remark-slide-scaler");
  if (!r) return;
  s.type = "text/css"; s.innerHTML = "@page {size: " + r.style.width + " " + r.style.height +"; }";
  d.head.appendChild(s);
})(document);

(function(d) {
  var el = d.getElementsByClassName("remark-slides-area");
  if (!el) return;
  var slide, slides = slideshow.getSlides(), els = el[0].children;
  for (var i = 1; i < slides.length; i++) {
    slide = slides[i];
    if (slide.properties.continued === "true" || slide.properties.count === "false") {
      els[i - 1].className += ' has-continuation';
    }
  }
  var s = d.createElement("style");
  s.type = "text/css"; s.innerHTML = "@media print { .has-continuation { display: none; } }";
  d.head.appendChild(s);
})(document);
// delete the temporary CSS (for displaying all slides initially) when the user
// starts to view slides
(function() {
  var deleted = false;
  slideshow.on('beforeShowSlide', function(slide) {
    if (deleted) return;
    var sheets = document.styleSheets, node;
    for (var i = 0; i < sheets.length; i++) {
      node = sheets[i].ownerNode;
      if (node.dataset["target"] !== "print-only") continue;
      node.parentNode.removeChild(node);
    }
    deleted = true;
  });
})();
(function() {
  "use strict"
  /* Replace <script> tags in slides area to make them executable
   *
   * Runs after post-processing of markdown source into slides and replaces only
   * <script>s on the last slide of continued slides using the .has-continuation
   * class added by xaringan. Finally, any <script>s in the slides area that
   * aren't executed are commented out.
   */
  var scripts = document.querySelectorAll(
    '.remark-slides-area .remark-slide-container:not(.has-continuation) script'
  );
  if (!scripts.length) return;
  for (var i = 0; i < scripts.length; i++) {
    var s = document.createElement('script');
    var code = document.createTextNode(scripts[i].textContent);
    s.appendChild(code);
    scripts[i].parentElement.replaceChild(s, scripts[i]);
  }
  var scriptsNotExecuted = document.querySelectorAll(
    '.remark-slides-area .remark-slide-container.has-continuation script'
  );
  if (!scriptsNotExecuted.length) return;
  for (var i = 0; i < scriptsNotExecuted.length; i++) {
    var comment = document.createComment(scriptsNotExecuted[i].outerHTML)
    scriptsNotExecuted[i].parentElement.replaceChild(comment, scriptsNotExecuted[i])
  }
})();
(function() {
  var links = document.getElementsByTagName('a');
  for (var i = 0; i < links.length; i++) {
    if (/^(https?:)?\/\//.test(links[i].getAttribute('href'))) {
      links[i].target = '_blank';
    }
  }
})();</script>

<script>
slideshow._releaseMath = function(el) {
  var i, text, code, codes = el.getElementsByTagName('code');
  for (i = 0; i < codes.length;) {
    code = codes[i];
    if (code.parentNode.tagName !== 'PRE' && code.childElementCount === 0) {
      text = code.textContent;
      if (/^\\\((.|\s)+\\\)$/.test(text) || /^\\\[(.|\s)+\\\]$/.test(text) ||
          /^\$\$(.|\s)+\$\$$/.test(text) ||
          /^\\begin\{([^}]+)\}(.|\s)+\\end\{[^}]+\}$/.test(text)) {
        code.outerHTML = code.innerHTML;  // remove <code></code>
        continue;
      }
    }
    i++;
  }
};
slideshow._releaseMath(document);
</script>
<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
(function () {
  var script = document.createElement('script');
  script.type = 'text/javascript';
  script.src  = 'https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-MML-AM_CHTML';
  if (location.protocol !== 'file:' && /^https?:/.test(script.src))
    script.src  = script.src.replace(/^https?:/, '');
  document.getElementsByTagName('head')[0].appendChild(script);
})();
</script>
  </body>
</html>
